This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption.
BPC-157 is one of the most-studied research-grade compounds of the last 25 years, and it has one of the stranger origin stories in modern compound science. It comes from a partial sequence of a protein found in human gastric juice.
Pavle Sikiric and his team at the University of Zagreb first isolated and characterized the fragment in the early 1990s, and they have published more than 100 preclinical papers tracking what it does in cells, animals, and tissue models ever since. Sikiric et al. (2013) in Current Pharmaceutical Design laid out the cytoprotective framework that most later work builds on (PMID: 22950504).
This guide reviews what preclinical research actually reports about BPC-157: its structure, the pathways it appears to touch, the specific studies that anchor the field, how it compares to TB-500 in the popular combined research format, and how researchers handle it at the bench. Everything here is for laboratory research use only.
Before going deep, here is the shape of what preclinical literature reports about BPC-157. Every claim below is grounded in a peer-reviewed study cited in the References section.
The abbreviation stands for Body Protection Compound-157. The 157 refers to the position of the fragment within the original parent protein sequence that Sikiric’s Zagreb group identified in the early 1990s.
The parent protein itself is present in human gastric juice. the mildly acidic fluid the stomach uses to break down food. and appears to have a housekeeping role in maintaining the integrity of the stomach lining. Researchers isolated the smallest active fragment they could and found the 15-amino-acid sequence still produced the cytoprotective effects they were tracking in rat models.
The primary sequence is GEPPPGKPADDAGLV. that is, glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine, valine.
Two features stand out. First, the run of three consecutive prolines gives the compound a rigid, kinked backbone that resists proteolytic breakdown. Second, the molecule has no cysteines, so it does not form disulfide bonds. That combination is why BPC-157 is unusually stable in aqueous solution compared to compounds of similar length. a practical consideration for laboratory handling.
Molecular weight is approximately 1,419 Da. As a lyophilized powder it appears as a white, amorphous solid. It dissolves readily in bacteriostatic water and in standard saline buffers.
| Property | Value |
|---|---|
| Sequence | GEPPPGKPADDAGLV |
| Length | 15 amino acids (15-amino-acid compound) |
| Molecular weight | ~1,419 Da |
| Disulfide bonds | None |
| Solubility | Water-soluble; stable in aqueous buffers |
| Parent protein source | Human gastric juice protein |
Here is where BPC-157 gets interesting, and where a lot of the confusion around it comes from. Most drug molecules bind one receptor and produce a cascade. BPC-157 does not appear to work that way.
Instead, Sikiric’s group and independent labs have reported that the compound seems to nudge a network of repair-related signaling proteins at once. No single receptor has been identified as the primary target. Because of that, papers often describe BPC-157 as “cytoprotective” or “pleiotropic” rather than as an agonist of a specific receptor family.
The most concrete mechanistic finding is on blood vessel formation. Hsieh and colleagues (2017) reported in Journal of Biomedical Science that BPC-157 influenced VEGFR2 activity and downstream Akt-eNOS signaling in endothelial cell models (PMID: 28536784). VEGFR2 is the primary receptor by which cells sense vascular endothelial growth factor, the main signal telling tissue to build new capillaries. If BPC-157 modulates that receptor’s activity, it plausibly connects to the tissue-repair effects reported elsewhere. new tissue needs new blood supply.
A second recurring finding is interaction with nitric oxide (NO) signaling. Nitric oxide is a small gas molecule that acts as a paracrine signal. cells release it locally, and nearby cells respond. It regulates blood flow, immune activity, and, importantly for repair biology, endothelial function.
Sikiric et al. (2014) in Current Neuropharmacology reviewed a series of rat experiments in which BPC-157 continued to produce measurable effects even when the animals were co-administered L-NAME, an NO synthesis blocker (PMID: 25415964). That is unusual. It suggests BPC-157 does not simply act through the NO pathway. it either has NO-independent activity or interacts with the system in ways that are not blocked by classical NO inhibition.
Chang and colleagues (2011) at the National Yang-Ming University in Taiwan ran a fibroblast experiment that stands out. They took tendon-derived fibroblasts. the cells that build and maintain tendon tissue. and exposed them to BPC-157 in culture. They then measured expression of the growth hormone receptor on those cells. Expression increased. The paper, published in Journal of Applied Physiology, is one of the most-cited pieces of mechanistic evidence in the BPC-157 literature (PMID: 21030672).
What that finding suggests, in plain terms: BPC-157 may make tendon cells more responsive to circulating growth hormone, which is a known driver of tissue repair. It does not mean BPC-157 is growth hormone. It means the compound appears to influence the antenna, not the signal.
“BPC-157 counteracts the adverse effects of NSAIDs and other harmful conditions in various organs.”
, Sikiric et al. (2013), Current Pharmaceutical Design, PMID: 22950504
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. BPC-157 is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
The BPC-157 literature is broad but concentrated. A relatively small number of primary papers do most of the work; everything else builds on them. Here are the anchor studies researchers reference most.
Sikiric’s 2013 Current Pharmaceutical Design paper is the standard reference for the overall framework (PMID: 22950504). It reviews more than a decade of the Zagreb group’s work in rat models. gastric ulcer models, colitis models, liver injury models, NSAID-toxicity models. and argues that BPC-157 produces a consistent tissue-protection pattern across organ systems. It is the paper cited when someone describes BPC-157 as “cytoprotective.”
The Chang paper in Journal of Applied Physiology is the single most-cited piece of cellular-level mechanistic data (PMID: 21030672). Rat tendon fibroblasts, in culture, exposed to BPC-157, showed increased expression of the growth hormone receptor. The paper is important because it moves the conversation from whole-animal observation to a specific cellular event.
The Krivic paper in Journal of Orthopaedic Research is one of the classic whole-animal tendon studies (PMID: 16879417). Rats received a full Achilles tendon transection. BPC-157 treatment was reported to influence the healing markers the researchers tracked over the recovery window.
The Hsieh paper in Journal of Biomedical Science anchors the angiogenesis story (PMID: 28536784). Endothelial cell cultures, BPC-157 exposure, and downstream measurement of VEGFR2-Akt-eNOS signaling. This is the paper that gives the multi-pathway framework a concrete receptor to point at.
The 2014 Current Neuropharmacology review is the reference for the NO-system story (PMID: 25415964). It compiles rat studies in which BPC-157 continued to produce effects under L-NAME co-administration, arguing for an NO-related but not NO-dependent mechanism.
BPC-157 and TB-500 (Thymosin Beta-4 fragment) are frequently supplied and studied as a combined lyophilized format. The reasoning is mechanistic: the two compounds appear to touch distinct but complementary repair pathways.
BPC-157, as discussed above, seems to influence angiogenic and growth-factor-receptor signaling. TB-500, in preclinical work by Smart and colleagues (2007) in Nature, has been reported to influence actin polymerization and cell migration during tissue repair (PMID: 17554337). Actin is the cytoskeletal protein cells use to physically crawl into a wound bed. If one compound is nudging blood supply and the other is nudging cellular movement, the pairing has a plausible logic in a research-protocol sense.
Nothing about the underlying compounds changes when they are supplied as a co-lyophilized blend. Each compound retains its individual stability profile. The blend format simplifies reconstitution and reduces the number of vials researchers handle in a given experimental protocol. Batch-level identity and purity for each component should be documented on the Certificate of Analysis for the blend.
The blend is not a fixed pharmacological entity. It is two research-grade compounds in one vial. Any comparison to prescription drug combinations is inappropriate. BPC-157 and TB-500 are both research compounds, not approved therapeutics.
Researchers evaluating BPC-157 for a preclinical repair-model protocol usually compare it to two adjacent compounds: TB-500 (as discussed) and, more recently, PDA (Pentadeca Arginate), a modified 15-amino-acid compound with an added arginate salt.
| Feature | BPC-157 | TB-500 | PDA |
|---|---|---|---|
| Structural class | 15-amino-acid compound (15 aa) | TB4-derived fragment (~17 aa) | Modified 15-amino-acid compound |
| Primary pathway (preclinical) | Angiogenic / GH-receptor / NO | Actin polymerization, cell migration | Overlaps BPC-157 (less data) |
| Peer-reviewed evidence base | Broad (~100+ preclinical papers) | Moderate (thymosin family well-studied) | Emerging / limited |
| Stability | High in aqueous buffer | Moderate | Reported improved vs BPC-157 |
The following section describes properties of the compound, not directives to any reader. Actual protocol design is the responsibility of the institutional research team.
BPC-157 is typically supplied as a lyophilized powder. freeze-dried under vacuum. In that state, stored at –20°C or colder in a sealed vial, the compound is stable for extended periods. Room-temperature storage of the lyophilized form is possible for shorter windows but shortens the usable shelf life.
The standard laboratory diluent for reconstitution is bacteriostatic water. sterile water containing 0.9% benzyl alcohol as a preservative. Sterile water without preservative is also used for single-day work. Once reconstituted, BPC-157 is generally reported as stable for 2–4 weeks at 2–8°C, with longer stability under freezing conditions if the reconstituted volume is aliquoted to avoid repeated freeze-thaw cycles.
Identity and purity should be verified on a batch basis by HPLC and mass spectrometry. HPLC quantifies purity as a percentage; mass spectrometry confirms identity by measuring the exact molecular weight of the compound against the theoretical value calculated from the sequence.
Two developments in the last two years are worth noting.
First, the mechanistic literature has continued to broaden. Additional endothelial-cell work has expanded on the Hsieh 2017 VEGFR2 findings, and rodent gut-brain axis studies have suggested BPC-157 activity may extend to enteric nervous system signaling. None of this has fundamentally changed the framework Sikiric proposed. it has added detail to it.
Second, regulatory posture has hardened. The FDA placed BPC-157 on its 2023 list of substances not approved for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which explicitly restricts pharmacy compounding of the compound. That does not affect the research-use-only status of BPC-157 as an analytical-grade laboratory reference material, but it does mean any framing of BPC-157 as a therapeutic product is inconsistent with U.S. regulatory position.
Because BPC-157 is a research compound not manufactured under GMP for clinical use, the analytical documentation supplied with a batch is the primary quality signal. Researchers evaluating a supplier should look for the following.
The Vitro Labs Certificates of Analysis page publishes batch-level documentation for the BPC-157 + TB-500 blend and other analytical-grade biochemical reference standards in the catalog.
⚠️ Research Disclaimer: This article is for educational and informational purposes only. All compounds discussed are research chemicals for laboratory use only and are not for human consumption.
BPC-157 is a 15-amino-acid compound. a 15-amino-acid fragment. derived from a partial sequence of a larger protein found in human gastric juice. Pavle Sikiric’s group at the University of Zagreb first isolated and characterized the fragment in the early 1990s and has published extensively on its cytoprotective activity in rat models since then (Sikiric et al., 2013, PMID: 22950504). It is supplied as an analytical-grade biochemical reference standard for laboratory research use only.
BPC-157 and TB-500 appear to touch distinct but complementary repair-related pathways in preclinical models. BPC-157 has been reported to influence angiogenic signaling (via VEGFR2, per Hsieh et al., 2017, PMID: 28536784) and growth-hormone receptor expression on tendon fibroblasts (Chang et al., 2011, PMID: 21030672), while TB-500 has been reported to influence actin polymerization and cell migration (Smart et al., 2007, PMID: 17554337). The combined format is a research convenience. the two compounds retain their individual properties.
No single receptor has been identified as the primary target. Preclinical literature describes BPC-157 as pleiotropic or cytoprotective, with reported activity across several repair-related pathways at once. VEGFR2-mediated angiogenesis, nitric oxide system interactions that persist even under L-NAME co-administration (Sikiric et al., 2014, PMID: 25415964), and growth-hormone receptor upregulation on tendon-derived fibroblasts. The multi-pathway framework is one of the open mechanistic questions in the field.
Yes, relatively so. The sequence contains three consecutive prolines that produce a kinked, protease-resistant backbone, and it has no cysteines and therefore no disulfide bonds to reduce. In lyophilized form, BPC-157 is stable for extended periods at –20°C or colder. Once reconstituted in bacteriostatic water, it is generally reported as stable for 2–4 weeks at 2–8°C, with longer stability under freezing conditions when aliquoted to avoid repeated freeze-thaw cycles.
No. BPC-157 is not approved for human consumption. In 2023 the FDA placed BPC-157 on the list of substances not approved for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. As an analytical-grade biochemical reference standard, it is supplied strictly for in vitro research, analytical method development, identity verification, and laboratory evaluation by qualified research customers. It is not intended for human or animal consumption, therapeutic use, or clinical use.
Identity is confirmed by mass spectrometry. measuring the observed molecular mass against the theoretical mass calculated from the GEPPPGKPADDAGLV sequence (~1,419 Da). Purity is quantified by HPLC, which separates the compound from any synthesis byproducts and reports the fraction of total peak area attributable to the target compound. Batch-specific Certificates of Analysis from a named independent analytical laboratory. with methodology documented, not just a summary percentage. are the reference standard.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. BPC-157 is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
